Glutamate Receptor Divergence and Pharmacological Implications

The recent study from Yale (Naples et al., 2025) claiming that autistic adults have reduced mGlu5 receptor availability is another piece in a long trail of fragmented science.

For decades, autistic people have been used as subjects in studies that isolate a single brain receptor, a lone circuit, or a narrow behavioural pattern. These isolated findings are often then projected back onto the person as if they are potentially causal of autism itself. This study measures lower mGlu5 availability in autistic adults using PET imaging, and then subtly implies that this may be a key factor.

MGlu5 is a glutamate receptor - a regulator of excitatory signalling in the brain. It’s part of the larger ecosystem that balances stimulation and inhibition, often referred to as the E/I (excitation/inhibition) balance. Glutamate sensitivity is part of the autistic experience, and this presents in a variety of ways such as sensory overload and migraines to anxiety, sleep disturbance, and digestive issues.

Mainstream science often operates as if each molecular finding is potential causal, rather than a consequence or corollary of a divergent developmental trajectory. A downstream marker is examined - a receptor change, a structural difference, a brainwave pattern - and then it is interpreted like it is the origin or a key to pathology.

Reduced mGlu5 availability does not necessarily mean “dysfunction” in the way the word is often used. It may be:

• A protective (epigenetic) downregulation after years of glutamate overexposure.

• A reflection of genetic differences in excitatory set-point.

• Or a compensatory adaptation in the context of a more sensitive and perceptive neurotype.

There’s an irony here that autistic people will likely recognise: for many years, autism was symbolised by a jigsaw puzzle piece (some people still use it) - an icon that the majority now reject due to its history. In a strange way, that symbol has come full circle, because researchers are continuously doing just that: pulling out disconnected pieces of the divergent profile and treating them like they represent the whole picture.

• Glutamate receptors.

• Brain volumes.

• White matter lesions.

• Eye-tracking patterns.

• Collagen.

• Repetitive behaviours.

• Gastro.

• Genetics.

• Inflammation.

• Mitochondria.

Every study picks up a new piece of the jigsaw and the author(s) hold it up in silo looking for the explanation. It never is; because neurodivergence isn’t a jigsaw - it’s an entire living system. It is a full-body, full-brain, genetically influenced, environmentally modulated way of being. You cannot learn about music by dismantling a saxophone into pieces and examining and interpreting each component separately. That is the way science currently operates; without integrated understanding, fragmenting presentations across disciplines and zooming in.

When researchers ignore that, when they chase markers as if they are causes, they not only miss the forest for the trees - they flatten the dignity of those they claim to study. A scientific paradigm that integrates neurodivergence as a coherent, adaptive system shaped by both biology and context is needed.

That means:

• Stopping the reflex to pathologise every difference.

• Abandoning causality-chasing in downstream measurements.

• Studying divergence as an integrated systemic configuration in need of systemic support.

• And listening to those who live it, not just imaging their brains.

The reduced mGlu5 availability is a meaningful piece of data, but it is not causal. It does not require 'targeted therapeutics' aside from cessation or reduction of glutamate/MSG (Monosodium Glutamate) containing medical interventions.

Pharmacology

Monosodium glutamate is a formally declared excipient in FluMist (live attenuated influenza vaccine, administered intranasally):

“Non-medicinal ingredients: Arginine hydrochloride, dibasic potassium phosphate, gelatin hydrolysate (porcine Type A), gentamicin (a trace residual), monobasic potassium phosphate, monosodium glutamate, ovalbumin (a trace residual), and sucrose.”

Even though FluMist is a nasal spray, not an injection, its route of administration is still highly invasive neurologically:

• The olfactory nerve pathway provides direct access to the central nervous system (CNS).

• Unlike ingestion (which goes through the gastrointestinal (GI tract), intranasal delivery bypasses the blood-brain barrier (BBB).

• This route is used intentionally in pharmacology to deliver drugs into the CNS.

For divergent individuals with glutamate sensitivity, impaired GABA balance, or connective tissue-related blood-brain barrier permeability, this raises risk.

Monosodium glutamate is also listed as an excipient in some, but not all, MMR and MMRV vaccines used in the UK:

• For MMR vaccines, M-M-RvaxPro contains monosodium L-glutamate, while Priorix does not list monosodium glutamate as an excipient.

• For MMRV vaccines, ProQuad contains monosodium glutamate, while Priorix-Tetra does not list monosodium glutamate as an excipient.

This means that exposure to monosodium glutamate through MMR or MMRV vaccination is brand-dependent. This distinction is important for informed consent, particularly where there are concerns about glutamatergic signalling, glutamate receptor variation, excitatory–inhibitory balance, or individual pharmacological sensitivity. Parents or patients can ask the GP surgery, vaccination clinic, or NHS provider which specific vaccine brand will be used. They can also request the Patient Information Leaflet or Summary of Product Characteristics before vaccination to ensure they are informed.

Injected monosodium glutamate is not comparable to dietary glutamate, because it bypasses the normal digestive processes that regulate absorption, metabolism, and gut–immune interaction. Although the quantity used as a vaccine excipient is small, the developmental timing and size of the recipient, alongside genomic factors should be considered. The route of exposure is also pharmacologically different when injecting: it is introduced directly into tissue alongside immune-stimulating vaccine components, making it a distinct risk consideration for individuals with unusual glutamatergic, immune, or neuroinflammatory

Monosodium glutamate is a known excitotoxin in susceptible terrain:

• It can overstimulate NMDA and AMPA glutamate receptors, particularly in the limbic system and hypothalamus.

• In animal studies, neonatal intranasal MSG administration has been used to induce excitotoxic brain damage.

• For individuals with GAD1/GAD2, GRIN2B, MTHFR, SLC1A1, or other terrain-impairing variants, this can trigger a neuro-inflammatory or neurotoxic response.

FluMist nasal flu spray and the MMR/MMRV vaccines may therefore be especially risky for:

• Neurodivergents.

• People with glutamate-related migraines, seizures, or sensory overload.

• Anyone with connective tissue divergence, BBB vulnerability, mast cell activation, or mitochondrial divergence.

Progressive clinical practice must acknowledge scientific research on divergence in its entirety, and personalise pharmaceutical interventions to ensure patient safety.

Link to study: https://doi.org/10.1176/appi.ajp.20241084

Image: Sistema nervoso recettori tattili - unknown author, 19th century, Museo di Anatomia Comparata “Giovanni Battista Grassi”, Sapienza University of Rome.

Contact

Reach out with questions or collaboration ideas.

Email

AChambers@divergentgenomics.org

© Alexandra Chambers 2026. All rights reserved.